-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253

Benzinga·09/03/2026 16:28:40
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $249 to $253.